EXPEDEON
DGAP-News: SYGNIS AG / Key word(s): Product Launch PRESS RELEASE SYGNIS introduces 2view unique Western blot detection technology - Offers two modes of detection from a single antibody - Fast visible detection of analytes at nanogram level - Enhanced chemi-luminescence detection down to picogram level - Easy to use with a single incubation Heidelberg, Germany and Cambridge, UK, 09 May 2018 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the introduction of 2view(TM), a unique detection method optimised for Western blotting, under its Expedeon brand name. 2view(TM) is an innovative double labeled secondary antibody that enables extended detection within the widely used Western blot application. The product consists of a ternary complex developed using the company's world leading InnovaCoat(R) and Lightning-Link(R) technology. 2view(TM) secondary antibodies are labeled simultaneously with a visible (InnovaCoat(R) GOLD nanoparticles) and proprietary chemi-luminescent enzymatic detection system. The gold nanoparticles enable fast visible detection at nanogram level whereas the enzymatic detection mechanism enhances sensitivity down to picogram levels of protein. Expedeon currently offers a wide range of products within the Western blot market, expected to reach $730.7 million by 2021, including its InstantBlue(TM) staining and Lightning-Link(R) primary antibody labeling technologies. The launch of 2view(TM) further opens up the Western blot market for the company, as well as providing access to the secondary antibody market which was estimated at $400 million in 2017, as well as complementing the company's range of secondary reagents. Expedeon will market this product through its direct sales and distribution channels and will also be looking to exploit the technology through OEM and licensing opportunities with antibody manufacturers. Dr. Nick Gee, Chief Technology Officer, SYGNIS, said: "We are highly committed to expanding our range of cutting-edge tools and services to simplify processes and increase efficiency in the lab. The introduction of the 2view(TM) Western blot detection technology will make a significant difference to many researchers."
/ SYGNIS AG About SYGNIS AG: www.sygnis.com ### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ### Additional features: Document: http://n.eqs.com/c/fncls.ssp?u=CSOHHWIWAX Document title: 2View_Eng
09.05.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
| Language: | English |
| Company: | SYGNIS AG |
| Waldhofer Str. 104 | |
| 69123 Heidelberg | |
| Germany | |
| Phone: | +49 (0) 6221 3540 125 |
| Fax: | +49 (0) 6221 3540 127 |
| E-mail: | investors@sygnis.com |
| Internet: | www.sygnis.com |
| ISIN: | DE000A1RFM03 |
| WKN: | A1RFM0 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| End of News | DGAP News Service |
683699 09.05.2018
